Influence of the anterior chamber angle pigmentation grade on the hypotensive efficacy of the Trilaktan in patients with primary open-angle glaucoma

PURPOSE: To analyze the influence of the anterior chamber angle pigmentation on the hypotensive effect of 0.005% of Russian latanoprost (Trilactan, “Solopharm”) in patients with primary open-angle glaucoma (POAG).
METHODS: The study was based on clinical and functional data of 120 patients (150 eyes) aged 42 to 87 years with primary open-angle glaucoma. The early stage of glaucoma was diagnosed in 102 (68%) eyes, moderate — in 36 (24%) eyes, advanced stage — in 12 (8%). Patients were divided into three groups: patients with treatment-naïve glaucoma; patients with a previously diagnosed POAG who received hypotensive therapy (β-blockers, or inhibitors of carbonic anhydrase); patients who received monotherapy with prostaglandin analogues for less than 2 months. Trilactan was administered once a day (at 8 pm). The hypotensive effect was evaluated after 1, 4 and 8 weeks. The observation period lasted 8 weeks.
RESULTS: The intraocular pressure reduced by 30% from the baseline level of tonometric intraocular pressure (IOP). On the 4th week of observation the hypotensive effect reached 32%, as an additional drug up to 20%. There was no statistically significant dependence between hypotensive effect and the anterior chamber angle pigmentation grade.
CONCLUSION: Trilactan showed hypotensive effect both in monotherapy and in combination with other antihypertensive drugs, comparable to the original drug. The effect of prostaglandin analogues on the condition of the trabecular meshwork, and an improvement of trabecular outflow seem promising for further studies.

1. Resnikoff S., Pascolini D., Etya’ale D., Kocur I. et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004; 82(11):844-851. doi: 10.1136/bjo.2005.081224.

2. Quigley H.A., Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90(3):262-267. doi: 10.1136/bjo.2005.081224.

3. Freeman E.E., Munoz B., West S.K., Jampel H.D. et al. Glaucoma and quality of life: the Salisbury eye evaluation. Ophthalmol. 2008; 115(2):233–238. doi: 10.1016/j.ophtha.2007.04.050.

4. European Glaucoma Society. Terminology and Guidelines for Glaucoma. 4th ed. Savona, Italy: PubliComm; 2014. doi: 10.1136/bjophthalmol-2016-egsguideline.001.

5. Hyman L.G., Komaroff E., Heijl A., Bengtsson B. et al. Early Manifest Glaucoma Trial Group. Treatment and vision-related quality of life in the early manifest glaucoma trial. Ophthalmol. 2005; 112(9): 1505–1513. doi: 10.1016/j.ophtha.2005.03.028.

6. Heijl A., Bengtsson B., Chauhan B.C., Lieberman M.F. et al. A compari son of visual field progression criteria of 3 major glaucoma trials in early manifest glaucoma trial patients. Ophthalmol. 2008; 115:1557–1565. doi: 10.1016/j. ophtha.2008.02.005.

7. Gillespie B.W., Musch D.C., Guire K.E., Mills R.P. et al. The collabora tive initial glaucoma treatment study: Baseline visual field and test retest variability. Invest Ophthalmol Vis Sci. 2003; 44:2613–2620. doi: 10.1167/iovs.02-0543.

8. Ernest P.J., Schouten J.S., Beckers H.J., Hendrikse F. et al. An evi dence-based review of prognostic factors for glaucomatous visual field progression. Ophthalmol. 2013; 120(3):512–519. doi: 10.1016/j.ophtha.2012.09.005.

9. Chauhan B.C., Mikelberg F.S., Balaszi A.G., LeBlanc R.P. et al. Canadi an Glaucoma Study: 2. Risk factors for the progression of open-angle glaucoma. Arch Ophthalmol. 2008; 126:1030–1036. doi: 10.1001/archopht.126.8.1030.

10. Adatia F.A., Damji K.F. Chronic open-angle glaucoma. Review for primary care physicians. Can Fam Physician. 2005; 51:1229–1237.

11. Bagnis A., Papadia M., Scotto R., Traverso C.E. Current and emerging medical therapies in the treatment of glaucoma. Expert Opin Emerg Drugs. 2011; 16(2):293–307. doi: 10.1517/14728214.2011.563733.

12. Curran M.P., Orman J.S. Bimatoprost/timolol: a review of its use in glaucoma and ocular hypertension. Drugs Aging. 2009; 26(2): 169–184. doi: 10.2165/0002512-200926020-00008.

13. Gheith M.E., Mayer J.R., Siam G.A., Monteiro de Barros D.S. et al. Managing refractory glaucoma with a fixed combination of bima toprost (0.03%) and timolol (0.5%). Clin Ophthalmol. 2008; 2(1): 15–20. doi: 10.2147/opth.s1175.

14. McKinnon S.J., Goldberg L.D., Peeples P., Walt J.G. et al. Current management of glaucoma and the need for complete therapy. Am J Manag Care. 2008; 14(1):20–27.

15. Kass M.A., Heuer D.K., Higginbotham E.J., Johnson C.A. et al. The Ocular Hypertension Treatment Study: a randomized trial deter mines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120(6):701–713. doi: 10.1001/archopht.120.6.701.

16. Heijl A., Leske M.C., Bengtsson B., Hyman L. et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002; 120(10):1268–1279. doi: 10.1001/archopht.120.10.1268.

17. Garway-Heath D.F., Crabb D.P., Bunce C., Lascaratos G. et al. Latanoprost for open-angle glaucoma (UKGTS): A randomised, multicentre, placebo-controlled trial. Lancet. 2015; 385:1295–1304. doi: 10.1016/S0140-6736(14)62111-5.

18. van der Valk R., Webers C.A., Schouten J.S., Zeegers M.P. et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: A meta-analysis of randomized clinical trials. Ophthalmol. 2005; 112:1177–1185. doi: 10.1016/j.ophtha.2005.01.042.

19. Konstas A.G., Maltezos, A.C., Gandi S., Hudgins A.C. et al. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am J Ophthalmol. 1999; 128:15–20.

20. Aung T., Chan Y.H., Chew P.T. EXACT Study Group. Degree of angle closure and the intraocular pressure-lowering effect of latanoprost in subjects with chronic angle-closure glaucoma. Ophthalmol. 2005; 112:267–271. doi: 10.1016/j.ophtha.2004.08.024.

21. Crawford K., Kaufman P.L. Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of uveoscleral outflow by prostaglandin F2 alpha. Arch Ophthalmol. 1987; 105:1112–1116. doi: 10.1001/archopht.1987.01060080114039.

22. Tatarintseva A.O. The experience of the first Russian latanoprost 0.005% (Trilactan) use in the treatment of primary open-angle glaucoma. Ophthalmology journal. 2018; 11(1):67-70. (In Russ.). doi: 10.17816/ov11167-70.

23. WHO Model List of EssentialMedicines. World Health Organization (October 2013) http://www.who.int/medicines/publications/essentialmedicines/en/

24. Patel S.S., Spencer C.M. Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging. 1996; 9(5):363–378. doi: 10.2165/00002512-199609050-00007. PMID 8922563.

25. Lei T.C., Masihzadeh O., Kahook M.I., Ammar D.A. et al. Imaging the effects of prostaglandin analogues on cultured trabecular meshwork cells by coherent anti-stokes Raman scattering. Invest Ophthalmol Vis Sci. 2013; 54(9):5972-5980. doi: 10.1167/iovs.13-12065.

26. Egorov E.A. Ophthalmopharmacology: guide for doctors. Moscow. GEOTAR-Media, 2009: 592 p. (In Russ.).

27. Toris C.B., Gabelt B.T., Kaufman P.L. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008; 53(1):107–120. doi: 10.1016/j.survophthal.2008.08.010.

28. Millard L.H., Woodward D.F., Stamer W.D. The role of the prostaglandin EP4 receptor in the regulation of human outflow facility. Invest Ophthalmol Vis Sci. 2011; 52:3506–3513.

29. Weinreb R.N., Aunq T., Medeiros F.A. The pathophysiology and treatment of glaucoma. JAMA. 2014; 311(18):1901-1911. doi: 10.1001/jama.2014.3192.

30. Lutjen-Drecoll E., Rohen J.W. Morphology of aqueous outflow pathways in normal and glaucomatous eyes. In: Rich R., Shields M.B., Krupin T., eds. The Glaucomas, 2nd ed. St. Louis: Mosby; 1996:89-123.

31. Anthony T.I., Pierce K.L., Stamer W.D., Regan J.W. Prostaglandin F2ɑ receptors in the human trabecular meshwork. Invest Ophthalmol Vis Sci. 1998; 39:315-321.

32. Alvarado J.A., Iguchi R., Martinez J., Trivedi S. et al. Similar effects of selective laser trabeculoplasty and prostaglandin analogs on the permeability of cultured Schlemm canal cells. Am J Ophthalmol. 2010; 150:254–264. doi: 1016/j.ajo.2010.03.012.

33. Сracknell K.P., Grierson I., Hogg P. et al. Melanin in the trabecular meshwork is assotiated with age, POAG but not latanoprost treatment. A mask morphometric Study. Exp Eye Res. 2006; 82:986-993.

34. Ogorodnikova V.Yu., Kuroedov A.V., Egorov A.E. Possible mechanisms of involving intracellular structures in the algorithm of metabolic reactions of glaucoma optic neuropathy. Glaucoma National Journal. 2011; 2:67-72. (In Russ.).

35. Wasyluk J.T., Piekarniak-Woźniak A., Grabska-Liberek I. The hypotensive effect of selective laser trabeculoplasty depending on iridocorneal angle pigmentation in primary open angle glaucoma patients. Arch Med Sci. 2014; 10(2):306-308. doi: 10.5114/aoms.2014.42583.

36. Sokolovskaya T.V., Doga A.V., Magaramov D.A., Kochetkova Y.A. Laser activation of trabecula in treatment of primary open-angle glaucoma. Ophthalmosurgery. 2015; 1:27-31. (In Russ.).

37. Wistrand P.J., Stjernschantz J., Olsson K. The incidence and timecourse of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 1997; 41:129–138. doi: 10.1016/s0039-6257(97)80020-3.

38. Chiba T., Kashiwagi K., Kogure S., Abe K. et al. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients. J Glaucoma. 2001; 10:406–410. doi: 10.1097/00061198-200110000-00008.

39. Hara T. Increased iris pigmentation after use of latanoprost in Japanese brown eyes (in Japanese). Nippon Ganka Gakkai Zasshi. 2001; 105:314–321. doi: 10.1016/s0021-5155(01)00432-4.

40. Ogawa I., Imai K. Iridial pigmentaion and hypertrichosis of eyelids caused by latanoprost instillation (in Japanese). J Eye. 2000; 17: 429–433.

41. Yamamoto T., Kitazawa Y. Iris-color change developed after topical isopropyl unoprostone treatment. J Glaucoma. 1997; 6:430–432. doi: 10.1097/00061198-199712000-00014.

42. Teus M.A., Arranz-Marquez E., Lucea-Suescun P. Incidence of iris color change in latanoprost treated eyes. Br J Ophthalmol. 2002; 86:1085-1088. doi: 10.1016/s0002-9394(02)02259-6.

43. Erichev V.P., Yakubova L.V. Clinical safety assessment of long-term use of Xalatan. Glaucoma. 2004; 1(3):76-79. (In Russ.).

44. Egorov E.A. Undesirable effects of hypotensive treatment. RMJ. Cliniсal Ophthalmology. 2007; 4:144-146. (In Russ.).

45. Ogawa I., Imai K. Iridial pigmentaion and hypertrichosis of eyelids caused by latanoprost instillation (in Japanese). J Eye. 2000; 17: 429–433.

46. Manual for using the Trilaktan LP-004254 at 19.04.17. (In Russ.).

47. Chiba T., Kashiwagi K., Chiba N., Ishijima K. et al. Comparison of iridial pigmentation between latanoprost and isopropyl unoprostone: a long term prospective comparative study. Br J Ophthalmol. 2003; 87:956-959. doi: 10.1136/bjo.87.8.956.

48. Zhang W.Y., Wan Po A.L., Dua H.S., Azuara-Blanco A. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open-angle glaucoma or ocular hypertension. Br J Ophthalmol. 2001; 85(8):983–990. doi: 10.1136/bjo.85.8.983.